Medication info
Bildaportmet Tablets 50/850 mg (Vildagliptin, Metformin Hydrochloride)

Bildaportmet Tablets 50/850 mg (Vildagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202301837 · Approved 2023.06.14 · Insurance code 671707310

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg daily are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is vildagliptin 100mg daily plus the current dose of metformin. The initial dose should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching to this medicine from combination therapy with vildagliptin and metformin may start at their current doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the current dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment with this medicine.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication has been developed to assist patients with type 2 diabetes in blood sugar control when used in combination with vildagliptin and metformin. By taking it alongside meal control and exercise therapy, blood sugar levels can be effectively managed, thereby helping to improve blood sugar control for patients.

How to take

Adult dose

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg daily are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine is vildagliptin 100mg daily plus the current dose of metformin. The initial dose should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching to this medicine from combination therapy with vildagliptin and metformin may start at their current doses of vildagliptin and metformin. 4. When used in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and a dose of metformin similar to the current dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment with this medicine.

Precautions

This medication is used to control blood sugar. It should not be used in patients with impaired kidney function. If kidney function is decreased, the drug can accumulate in the body and lead to serious side effects. Patients with weakened heart function, severe infections, severe trauma, or malnutrition should also be cautious. In such scenarios, it may be necessary to temporarily discontinue the medication. Before surgery, this medication should be stopped at least 48 hours before, and it can be resumed only after verifying that kidney function is normal post-surgery. It is safest for pregnant women, those who may become pregnant, and breastfeeding mothers not to take this medication. This drug may cause serious side effects such as hypoglycemia or lactic acidosis. Lactic acidosis is rare but can be life-threatening; symptoms such as weakness, abdominal pain, and difficulty breathing should prompt immediate medical attention. Additionally, excessive alcohol consumption should be avoided while taking this medication, as alcohol can increase the risk of lactic acidosis. Interactions may occur when this drug is taken with certain medications; therefore, it is essential to inform your doctor or pharmacist if you are taking other medications. Regular monitoring of kidney and liver function tests is recommended while on this medication, and periodic checks of vitamin B12 levels are advisable. Dizziness or drowsiness may occur; therefore, caution should be taken when driving or operating machinery. In case of overdose, immediate medical attention is required, and blood dialysis may be necessary. This medication is not recommended for children or adolescents under 18 years of age, as safety and efficacy have not been established. If blisters or ulcers occur on the skin while taking this medication, consult a doctor immediately. Lastly, this medication is not suitable for patients with type 1 diabetes who require insulin treatment, so caution should be exercised.

Side effects

Lactic acidosis, hypoglycemia, hepatitis, impaired liver function, elevated transaminase levels, angioedema, tremors, headaches, dizziness, fatigue, nausea, gastroesophageal reflux, diarrhea, bloating, chills, reduction in blood sugar, asthenia, hyperhidrosis, constipation, arthralgia, upper respiratory tract infections, rhinitis, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, decreased appetite, taste disorders, skin reactions (erythema, itching, urticaria), pancreatitis, urticaria, blisters, exfoliative skin lesions, severe and disabling arthralgia, cutaneous vasculitis, cholecystitis, dyspepsia, abdominal discomfort, gastrointestinal disturbances, increased serum amylase, increased lipase, blistering similar to pemphigoid, myalgia, paresthesia, fever, edema, swelling of the hands and feet, elevated creatine phosphokinase, elevated AST, increased C-reactive protein, elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. It should also be kept in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.